MAP2K7 and cancer: Another study pointed out that SHP2 small molecular allosteric inhibitor RMC-4550 decreases oncogenic-related Ras/Raf/MEK/Erk signaling to impair the growth of cancer-bearing Ras-GTP-dependent oncogenic BRAF mutation, NF1 loss, or nucleotide-cycling oncogenic Ras (Nichols et al., 2018).